黏蛋白-1和细胞角蛋白-20在食管癌中的表达及意义

Objective To investigate the expressions and clinical significances of MUC1-mRNA and CK20-mRNA in peripheral blood of esophageal cancer patients.Methods MUC1-mRNA and CK20-mRNA were detected in 53 patients with esophageal cancer,10 patients with esophageal benign tumor and 20 healthy volunteers by RT-PCR technique.Results The expressions of MUC1-mRNA,CK20-mRNA and combining group were 35.85 % (19/53),49.06 % (26/53) and 62.26 % (36/53) in peripheral blood of 53 esophageal cancer patients.In control group,there was no expression of MUC1-mRNA and CK20-mRNA in peripheral blood of 10 patients with benign esophageal disease and 20 healthy volunteers.The positive rate increased by combining test(x2 =11.0228,P ＜0.05).Conclusion MUC1-mRNA and CK20-mRNA might be specific and sensitive markers to detect circulating tumor cells in peripheral blood and their expressions are closely related to TNM stages of the esophageal cancer patients.The combining test might be of high value of the diagnosis of micrometastasis.     

Clinical value of cancer cells joint detection in peripheral blood plasma of thyroid cancer patients

We aimed to detect cytokeratin 19 （CK19） and polymorphic epithelial mucin 1 （MUC1） expression in peripheral blood of thyroid cancer patients, and investigate the clinical value of it as a diagnostic marker for circulating blood micrometastases. Methods： The flow cytometry （FCM） was used to detect and analyze CK19 and MUC1-expressing cells in peripheral blood of 491 thyroid cancer patients. Results： CK19 and MUC1 expression showed no statistically significant difference with gender and age in thyroid cancer patients （P 〉 0.05）, while had statistically significant difference with tumor size, lymph node stage and distant metastasis （P 〈 0.01）. The expression of CK19 and MUC1 were positively correlated （r = 0.628, P = 0.00）. Conclusion： CK19 is closely related to MUC1 expression, tumor size, extent of invasion and distant metastasis in peripheral blood of thyroid cancer patients. The circulating blood CK19 and MUC1 tests can help predict thyroid cancer micrometastases and prognosis.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

Detection of p53 gene mutation in plasma of patients with gastric cancer

Objective:To investigated p53 gene mutation in plasma of gastric cancer patients. Methods: DNA extracted from plasma and matched tumor and tumor-adjacent non-cancerous tissues of 96 gastric cancer patients, and DNA from 20 healthy volunteers were studied. Exon 5, 6, 7, and 8 of p53 were amplified by Polymerase Chain Reaction (PCR). The mutation status was analyzed by denaturing high-performance liquid chromatography (DHPLC), followed by direct sequencing of cases with aberrant chromatographic patterns. Results: Heterozygous mutations of p53 gene were detected in 19.9% (19/96) of primary tumor tissues and 5.2% (5/96) of corresponding plasma. All p53 gene mutations detected in plasma DNA consisted with mutations in the matched primary tumor samples.Neither the tumor-adjacent gastric mucosa tissues nor control plasma from healthy volunteers showed p53 gene mutation. No correlation was found between p53 mutation status and clinicopathological features of gastric cancer patients. Conclusion: p53 gene mutation in plasma can be detected in tissues and plasma of gastric cancer patients, which could be applied in screening and surveillance of this disease.     

肺癌患者外周血血小板活化标志物水平及其临床意义

Objective： To investigate the relationship between the activation markers of platelets and the lung cancer. Methods： Based on international stages of lung cancer in 1997, lung cancer patients of 120 cases diagnosed by pathology as well as with operation indication were selected as the experimental group. During the process of experiment, 60 cases concluded as healthy in the physical examination were chosen as control group. The activation markers of platelets were detected by FCM method. The experimental result would be processed by SPSS 11.5. Results： The level of activation markers of platelets in peripheral blood of lung cancer patients was significantly higher than those healthy people （P 〈 0.01）. The level of activation markers of platelets in peripheral blood of lung cancer patients on the seventh postoperative day was significantly lower than that before operation and on the first postoperative day （P 〈 0.01）. The level of activation markers of platelets in peripheral blood of lung cancer patients was closely related to the size of the primary tumor, lymph node status and stages, but not to the grade of cell differentiation, type of tumor, age, sex of the patients （P 〉 0.05）. Conclusion： Elevation of the level of activation markers of platelets in peripheral blood exists in lung cancer patients and the levels of activation marker of platelets plays an important role in tumor growth and lymphatic metastasis. The levels of activation markers of platelets maybe a predictor for prognosis.     

黏蛋白-1和细胞角蛋白-20在食管癌中的表达及意义

 目的　研究食管癌患者外周血黏蛋白-1（MUC1）和细胞角蛋白-20（CK20）表达情况及临床意义。方法　采用反转录聚合酶链反应（RT-PCR）方法检测53例食管癌患者外周血MUC1-mRNA和CK20-mRNA水平,以10例食管良性肿瘤患者及20名健康体检者为对照。结果　在良性肿瘤组及健康对照组中,MUC1-mRNA及CK20-mRNA均无表达,而在食管癌患者中的阳性率分别是35.85 %（19／53）和49.06 %（26／53）,二者联合检测阳性率为62.26 %（36／53）,较单项阳性率高（χ2＝11.0228,P＜0.05）。二者在食管癌患者中的表达与患者性别、年龄及肿瘤分化程度无明显相关性,而与肿瘤临床分期明显相关。结论　MUC1-mRNA和CK20-mRNA作为食管癌肿瘤标志物具有较高的敏感性及特异性;其表达与食管癌的临床分期密切相关;两种标志物联合检测有助于提高食管癌微转移的检出率。     

Survivin—mRNA在肺癌纤维支气管镜活检组织中的表达

目的：探讨纤维支气管镜活检组织Survivin—mRNA的表达对肺癌诊断的价值。方法：纤维支气管镜活检组织常规病理检查分为肺癌组和良性病变组,同时活检组织用RT—PCR方法检测Survivin—mRNA的表达。结果：46例肺癌组Survivin—mRNA表达明显高于17例肺部良性疾病组（P〈0．05）;肺癌纤支镜活检组织Survivin—mRNA表达与年龄、性别及组织类型无关（P〉0．05）;低分化NSCLCSurvivin—mRNA表达高于高、中分化NSCLC（P〈0．05）;m＋Ⅳ期NSCLCSurvivin—mRNA表达高于I＋Ⅱ期NSCLC（P〈0．05）;SCLC广泛期和局限朗Survivin-mRNA表达礁著陛．差异（P〉0．05）。结论：检测纤维支气管镜活检组织Survivin—mRNA的表达对肺癌的诊断,恶性程度判断及预后判断有一定的价值。     

Identification and validation of a 21-mRNA prognostic signature in diffuse lower-grade gliomas

Journal of Neuro-Oncology - Diffuse low-grade and intermediate-grade gliomas, also known as lower-grade gliomas (LGGs), are a class of central nervous system tumors. Overall survival varies greatly...     

MiR-126 Modulates Angiogenesis in Breast Cancer by Targeting VEGF-A -mRNA

Background: Breast cancer is most serious reasons of women death around worldwide result in increasing itsmorbidity and mortality. MicroRNAs are considered as significant regulators of cancer biological processes. The mainaim of this study is restoration of miR-126 could lead to modulate breast cell line and impairs their proliferation bytargeting vascular endothelial growth factor gene (VEGF-A). Methods: Breast cancer cell line (MCF7) was transfectedby miR-126 lipofectamine and negative miR control for 24 hr. Cytotoxic effects of miR-126 lipofectamine weredetermined by cell viability assay. Cell proliferation and cell cycle were quantitatively measured using PicoGreenassay and DAPI stain-flow cytometer analysis. For further investigation, Taq-Man real time PCR assay was performedto detect relative VEGF-A and miRNA-126 level. Results: MiR-126 was overexpressed in treated breast cancer cell(MCF7) compared with control cells. miR-126 expression has been associated –with a decrease in cell proliferationand arrested MCF7 cells at G1 phase. The study found that vascular endothelial growth factor is regulated by miR-126. Hence, VEGF-A is considered as functional vital and direct target to miR-126 in breast cancer cell line (MCF7).Conclusions: This study provided that manipulated miR-126 level may suggest a novel therapeutic approach in breastcancer treatment. However, an animal models study is needed to address and prove predictive ability of miR-126 onbreast cancer controlling.     

直肠癌外周静脉血CK20-mRNA的检测及其临床意义

目的检测直肠癌外周血细胞角蛋白(CK)20-mRNA并探讨其临床意义。方法采用RT-PCR方法,检测42例直肠癌术前外周静脉血CK20-mRNA。结果42例直肠癌中外周静脉血CK20-mRNA阳性14例,阳性率33.3%。随着病理分期的进展,CK20-mRNA阳性率升高;DukesC D期高于DukesA B期(P<0.01)。随访发现,外周静脉血CK20-mRNA阳性者远处转移率较高(28.6%)。结论外周静脉血CK20-mRNA的检测可提高直肠癌临床分期的准确性;外周静脉血CK20-mRNA阳性者,远处转移的可能性较大。     

Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells.

The matrix metalloproteinases (MMPs) are perceived as essential for tumour invasion and metastases. The purpose of this study was to determine the expression and cellular localisation of the 92 kDa type IV collagenase (MMP-9) protein and mRNA in human colorectal cancer (CRC). In CRC and matched normal mucosa specimens from 26 CRC patients, Northern blot hybridisation and Western blot analyses provide convincing evidence that MMP-9 is expressed in greater quantities in CRC than in normal tissue. The MMP-9 tumour to normal mucosa fold-increase (T/N) was 9.7 +/- 7.1 (mean +/- s.d.) (P < 0.001) for RNA and 7.1 +/- 3.9 (P < 0.001) for protein. The sites of MMP-9 mRNA and protein synthesis were colocalised in tumour stroma by in situ hybridisation and immunohistochemistry in 26 CRC samples. Both MMP-9 mRNA and protein signals were strongest in the population of stromal cells concentrated at the tumour-stroma interface of an invading tumour. Furthermore, MMP-9-positive cells were identified as macrophages using an antimacrophage antibody (KP1) in serial sections from ten CRC samples. Given the persistent localisation of MMP-9-producing macrophages to the interphase between CRC and surrounding stroma, our observations suggest that MMP-9 production is controlled, in part, by tumour-stroma cell interactions. Further studies are needed to determine the in vivo regulation of MMP-9 production from infiltrating peritumour macrophages.     

乳腺癌中DLC1 和DLC1-mRNA 的表达及其临床意义

目的:探讨乳腺癌中肝癌缺失基因1（deleted in liver cancer-1,DLC 1）和DLC 1-mRNA的表达及其临床意义。方法:应用原位杂交技术和免疫组织化学EnVision 二步法,检测52例乳腺浸润性导管癌和42例非癌乳腺组织（包括癌旁乳腺组织20例和乳腺纤维腺瘤22例）中DLC 1 和DLC 1-mRNA的表达,分析乳腺癌中DLC 1 和DLC 1-mRNA的表达与患者年龄、肿瘤最大直径、组织学分级、腋窝淋巴结转移和TNM分期等临床病理参数的相关性。结果:DLC 1 和DLC 1-mRNA在乳腺癌和非癌乳腺组织中的阳性表达率分别为（57.7% ,50.0%）和（92.9% ,90.5%）,DLC 1 和DLC 1-mRNA在乳腺癌中的表达率显著低于非癌乳腺组织（χ2=14.717,P=0.000;χ2=17.518,P=0.000）,差异均有显著统计学意义（P<0.001）。 乳腺癌中DLC 1 和DLC 1-mRNA的表达与组织学分级（rs=-0.811,P=0.000;rs=-0.422,P<0.05）、腋淋巴结转移（rs=-0.410,P<0.01;rs=-0.445,P<0.01）和TNM分期（rs=-0.319,P<0.05;rs=-0.405,P<0.05）均呈负相关;DLC 1-mRNA的表达与肿瘤最大直径（rs=-0.347,P<0.05）亦呈负相关。DLC 1 与肿瘤最大直径（rs=0.073）和DLC 1、DLC 1-mRNA的表达与患者年龄（rs=0.077;rs=0.008）的相关性均无统计学意义（P>0.05）。 结论:DLC 1 蛋白和DLC 1-mRNA在乳腺癌中呈低表达或失表达,在乳腺癌的恶性演进中扮演着重要角色。检测乳腺癌中DLC 1 和DLC 1-mRNA的表达,结合相关临床病理参数,可作为判断乳腺癌生物学行为和预后的一个参考指标。      

S19-mRNA expression in squamous cell carcinomas of the upper aerodigestive tract

BACKGROUND: The differential display method showed altered expression of ribosomal protein S19 gene in human head and neck squamous cell carcinoma (HNSCC) cell lines. MATERIALS AND METHODS: To verify these results, RT-PCR analysis was carried out in 18 HNSCC and 17 benign epithelial cell lines as well as 30 HNSCC and 8 reference tissue samples. In the HNSCC cells S19 mRNA expression was significantly reduced as compared to benign epithelial cells. RESULTS: Change of the S19 gene expression in surgical samples was detectable but not significant although the histopathological grading of the HNSCC biopsies correlated significantly with the S19 mRNA expression levels. The expression of ribosomal protein S6 and S14 genes were additionally analyzed using the same methods. CONCLUSION: High correlation was found between the expression of S6/S14 and S19 suggesting that changes in S19 gene expression might be the result of loss of ribosomes in HNSCC cells.     

肺腺癌及鳞癌MDR1-mRNA和MRP-mRNA表达的研究

观察３０例肺癌组织及癌肺组织ＭＤＲ１－ｍＲＮＡ及ＭＲＰ－ｍＲＮＡ的表达。方法：ＲＴ－ＰＣＲ方法。结果：ＭＤＲ１－ｍＲＮＡ在肺癌组织及癌旁肺组织的表达阳性率分别为４０．０％及１６．６７％（Ｐ＝０．０４５）,ＭＤＲ１－ｍＲＮＡ的表达与细胞分化程度,临床分期及病理类型无关;ＭＲＰ－ｍＲＮＡ在肺癌主癌旁肺组织的表达分别为４３．３３％及２６．６７％,ＭＲＰ＝ｍＲＮＡ的表达与细胞分化程度有关,低分者ＭＲＰ的表